Brand Name
Leqselvi
Generic Name
Deuruxolitinib
View Brand Information FDA approval date: June 25, 2025
Classification: Janus Kinase Inhibitor
Form: Tablet
What is Leqselvi (Deuruxolitinib)?
LEQSELVI™ is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants. LEQSELVI is a Janus kinase inhibitor indicated for the treatment of adults with severe alopecia areata. Limitations of Use: LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period
Summary: This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.